{"classes":[{"categories":[{"measurements":[{"comment":"Median survival was not calculable because at the end of the follow-up period, more than 50% of the participants were still alive.","groupId":"OG000","lowerLimit":"0.36","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"Median amount of time subject survives post therapy.","dispersionType":"95% Confidence Interval","groups":[{"description":"Cohort 1, Dose Level 1 - Lenalidomide 25mg by mouth (PO) was given on days 1 to 10, plus, etoposide phosphate, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R). During cycle 1, Etoposide 50mg/m\\^2/day, Vincristine 0.4 mg/m\\^2 /day, and Doxorubicin 10 mg /m\\^2/day were given as continuous intravenous infusion days 6 to 9. During cycles 2-6, Etoposide, Vincristine 0.4 mg/m\\^2 /day, and Doxorubicin were given as continuous intravenous infusion days 1 to 4. During cycles 2-6, doses of etoposide and doxorubicin were adjusted based on hematologic parameters during the previous cycle. During cycle 1, Prednisone 60 mg/m\\^2 /day PO days 6 to 10. During cycles 2-6, Prednisone 60 mg/m\\^2 /day PO days 1-5. During cycle 1, Cyclophosphamide 750 mg/m\\^2 was given on day 10. During cycles 2-6, Cyclophosphamide 750 mg/m\\^2 was given on day 5. Rituximab was administered on day 4 prior to the start of EPOCH during cycle 1 and on day 1 during cycles 2 to 6.","id":"OG000","title":"Lenalidomide+Etoposide Phosphate, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin & Rituximab"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"End of follow up period (5 years)","title":"(Phase II) Overall Survival in Treatment-naive Participants With Primary Effusion Lymphoma Treated With Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab (DA-EPOCH-R2) Reported Along With a 95% Confidence Interval","type":"PRIMARY","unitOfMeasure":"years"}